Mobio Interactive
AI-powered digital theragnostics platform using phone camera rPPG for personalized mental health therapy.
Website: https://www.mobiointeractive.com/
PUBLIC
| Name | Mobio Interactive |
| Tagline | AI-powered digital theragnostics platform using phone camera rPPG for personalized mental health therapy. |
| Headquarters | Singapore |
| Founded | 2015 [PitchBook] |
| Stage | Seed |
| Business Model | B2B2C |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | Southeast Asia |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding Label | Seed (total disclosed ~$2,400,000) |
Links
PUBLIC
- Website: https://www.mobiointeractive.com/
- LinkedIn: https://sg.linkedin.com/company/mobio-interactive
Executive Summary
PUBLIC Mobio Interactive is a nine-year-old Singaporean healthtech company building a hardware-free system to objectively measure and treat mental health conditions. This bet merits attention for its clinical validation and backing from a major strategic investor [Mobio Interactive, Unknown] [Johnson & Johnson, ~2023].
The company was founded in 2015 by a team led by neuroscientist Bechara Saab to address the subjectivity of traditional mental health assessments [PitchBook, Unknown] [The Org, Unknown]. Its core product is a digital theragnostics platform that uses a phone's camera and remote photoplethysmography (rPPG) to quantify psychological stress from a 30-second selfie. It then delivers personalized, adaptive therapy [Mobio Interactive, Unknown] [Crunchbase, Unknown].
The founding team combines scientific and technical leadership. Saab serves as CEO and Chief Scientist, Avetis Muradyan as CTO. Their commercial scaling experience in enterprise healthtech is less documented [Mobio Interactive, Unknown] [LinkedIn, Unknown].
To date, the company has disclosed approximately $2.4 million in total funding, including a seed round and a grant in 2023. J&J Impact Ventures is a notable investor [MobiHealthNews, Unknown] [Mobio Interactive, Aug 2023]. The business model targets B2B2C channels and aims to sell to healthcare providers, insurers, and telehealth networks seeking cost-saving preventative tools [Mobio Interactive, Unknown].
The critical watchpoints over the next 12-18 months are the translation of its 20+ claimed clinical studies into named commercial deployments. Scaling its modest funding base to drive revenue growth beyond early pilot projects will also matter [Mobio Interactive, Unknown] [ImpactAlpha, Unknown].
Data Accuracy: YELLOW -- Core facts like founding year and investor names are corroborated, but key traction and validation metrics are sourced primarily from the company.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Seed |
| Business Model | B2B2C |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Southeast Asia |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Seed (total disclosed ~$2,400,000) |
Company Overview
PUBLIC
Mobio Interactive was founded in 2015 in Singapore. It positions itself as a digital theragnostics company long before the recent wave of AI-driven mental health tools [PitchBook]. The founding team, led by CEO and Chief Scientist Bechara Saab, set out to address a fundamental gap in mental healthcare: the lack of objective, scalable biomarkers to personalize treatment [Mobio Interactive]. The company's core thesis, that stress and brain states could be quantified through a smartphone camera, has guided its development for nearly a decade.
Key milestones reflect a path focused on clinical validation and strategic backing. The company participated in the MedTech Innovator Asia Pacific accelerator program, a signal of its focus on regulated medical technology [Mobio Interactive, Aug 2023]. A significant inflection point was an investment from J&J Impact Ventures, the impact investing arm of Johnson & Johnson. This was announced to support the global scaling of its precision psychiatry platform [Johnson & Johnson, ~2023].
In August 2023, Mobio announced it had secured a grant, though the amount was not disclosed [Mobio Interactive, Aug 2023]. The company also formed a Growth Advisory Board in 2024 to guide its next phase of commercial expansion [Mobio Interactive].
Data Accuracy: YELLOW -- Founding year and location corroborated by PitchBook; key milestones and team roles cited from company sources and a J&J press release. Specific dates for some events are not publicly available.
Product and Technology
MIXED The core product is a digital theragnostics platform that uses a smartphone camera to measure psychological stress. It aims to replace subjective self-reports with objective, hardware-free biomarkers.
Mobio Interactive's platform is built on remote photoplethysmography (rPPG) technology. The system analyzes subtle changes in facial blood flow from a 30-second selfie video to quantify brain states associated with stress and anxiety [Mobio Interactive]. This data is then used to personalize and adapt digital psychotherapy programs. The company calls this process "digital theragnostics" [Mobio Interactive].
The company claims its approach has generated more than 3.5 million datapoints from over 425,000 selfie scans [ImpactAlpha]. These figures are not independently verified. The product is designed for integration into telehealth networks, hospital systems, and insurance platforms. It targets both clinicians and patients directly in a B2B2C model [Mobio Interactive].
The technical differentiation rests on the proprietary rPPG algorithm and the associated clinical validation. Mobio Interactive states its methods are supported by 20+ clinical studies and 19 peer-reviewed papers [Mobio Interactive]. The platform's output is intended to serve as a scalable, objective measure for prevention, real-time assessment, and treatment monitoring. It addresses what the company identifies as a "subjectivity gap" in mental health diagnostics [Mobio Interactive].
No specific details about the underlying AI model architecture, data pipeline, or security protocols are publicly disclosed. The team composition, described as scientists, clinicians, programmers, and designers [Mobio Interactive], suggests a cross-functional build. The public record lacks technical deep-dives from the engineering leadership.
Data Accuracy: YELLOW -- Core product claims are sourced from the company's website and a secondary press article. Key traction metrics (scans, datapoints) and clinical validation counts are company-reported and not independently corroborated.
Market Research and Opportunity
PUBLIC The market for digital mental health tools is expanding rapidly. It is driven by a persistent global treatment gap and growing acceptance of technology for scalable, objective care.
The total addressable market for digital mental health solutions is large but fragmented. While Mobio Interactive does not cite a specific TAM, analogous market research provides context. The global digital therapeutics market was valued at approximately $5.1 billion in 2022. It is projected to grow at a compound annual growth rate of 26.1% through 2030, according to a Grand View Research report cited by many industry analyses [Grand View Research, 2023].
Within this, the segment for AI-powered mental health platforms represents a significant and fast-growing portion. The company's focus on hardware-free, biomarker-driven assessment positions it within the precision psychiatry niche. This niche aims to address the subjectivity inherent in traditional diagnostic methods.
Key demand drivers for this category are well-documented. The global burden of mental health conditions continues to rise. Factors such as the COVID-19 pandemic's long-term psychosocial effects exacerbate it [World Health Organization]. Healthcare systems face severe provider shortages, creating pressure for scalable, lower-cost interventions.
The shift towards value-based care and preventive health models creates a financial incentive for tools that demonstrate measurable outcomes and cost savings, particularly among insurers and large employers. Mobio's targeting of payors and telehealth networks aligns directly with these tailwinds [Mobio Interactive].
Adjacent and substitute markets influence the opportunity. Traditional therapy and pharmaceutical interventions remain the primary substitutes, though they face access and stigma barriers. The wearable-based biometric monitoring market (e.g., devices tracking heart rate variability for stress) represents a parallel but hardware-dependent approach.
Mobio's wedge of using ubiquitous smartphone cameras attempts to bypass the adoption friction and cost associated with dedicated devices. Regulatory forces are a critical factor. Achieving regulatory approvals as a Software as a Medical Device (SaMD) or digital therapeutic in key markets like the United States, Europe, and Singapore is a significant hurdle. It is also a potential moat for validated platforms [Mobio Interactive].
Given the absence of specific, cited market segmentation numbers from the company, a comparative sizing table based on analogous public reports is provided below.
| Market Segment | Cited Size (Year) | Source | Notes |
|---|---|---|---|
| Global Digital Therapeutics | $5.1B (2022) | Grand View Research | Analogous market; projected 26.1% CAGR to 2030. |
The analyst takeaway is that Mobio operates in a large and validated growth market. Its specific served market (SAM) and serviceable obtainable market (SOM) remain undefined by public sources. The company's success will depend less on the overall market size. It will depend more on its ability to secure regulatory clearances and demonstrate superior clinical and economic outcomes compared to both traditional care and simpler digital wellness apps.
Data Accuracy: YELLOW -- Market sizing is based on an analogous third-party report; company-specific TAM/SAM/SOM is not publicly disclosed.
Competitive Landscape
MIXED
Mobio Interactive operates in a competitive map defined by the intersection of digital mental health, biometric sensing, and therapeutic delivery. Its primary claim to distinction rests on a hardware-free, camera-based measurement technique.
Competitive Map by Segment
The company's offering touches several distinct competitive segments, each with its own set of incumbents and challengers.
In the digital therapeutic (DTx) software segment, direct competitors include companies like Woebot Health and Big Health. They deliver structured, evidence-based cognitive behavioral therapy (CBT) and other interventions via mobile applications [PUBLIC]. These players compete on clinical validation and user engagement but typically rely on self-reported data for personalization.
The biometric sensing for mental health segment includes companies utilizing wearables (e.g., Oura Ring for stress, Empatica for physiological monitoring) and other contact-based sensors to provide objective data [PUBLIC]. Mobio's rPPG approach positions it as a challenger here. It aims to replace specialized hardware with ubiquitous smartphone cameras.
Adjacent substitutes include traditional telehealth and therapy platforms (BetterHelp, Talkspace) and enterprise wellness suites (Calm for Business, Headspace Health). These focus on service delivery and content libraries rather than objective biomarker integration [PUBLIC].
Defensible Edge and Durability
Mobio's current edge appears to be technological and regulatory. The company claims a proprietary dataset of over 425,000 scans and 3.5 million datapoints derived from its rPPG technology. This forms the foundation for its AI models [Mobio Interactive].
If exclusive and continuously growing from deployments, this dataset could create a short-term data moat. The claim of "clinically validated in 20+ studies" and 19 peer-reviewed papers suggests an early focus on regulatory and scientific credibility. This is a significant barrier in medical technology [Mobio Interactive].
This edge is perishable, however. The underlying rPPG computer vision techniques are an area of active academic and commercial research. Larger technology or healthtech firms could develop similar capabilities in-house or through acquisition. The durability of Mobio's edge will depend on its ability to convert clinical validation into patented IP, secure reimbursement codes, and establish exclusive commercial partnerships faster than competitors can replicate the science.
Exposure and Vulnerabilities
The company's most significant exposure is its go-to-market and scale. After nine years of operation and with approximately $2.4 million in total disclosed funding, Mobio lacks the capital war chest of well-funded DTx or wellness platforms that have raised hundreds of millions [Crunchbase, MobiHealthNews]. This limits its sales, marketing, and partnership development capabilities.
It is exposed to competitors that own the end-user relationship, such as telehealth platforms that could choose to build or white-label similar assessment tools. This would bypass Mobio's B2B2C model. While the technology is hardware-free, it requires user compliance for 30-second selfie scans. This is a friction point that more passive wearable-based competitors do not face.
18-Month Scenario
The most plausible competitive scenario over the next 18 months hinges on partnership execution and regulatory progress. The winner in this segment will likely be the company that successfully embeds its technology into a high-volume clinical or payer workflow. It would move from pilot to scaled deployment.
For Mobio, a win looks like a announced, multi-year contract with a national health system in Asia-Pacific or a global insurer. This would use its J&J Impact Ventures connection [Johnson & Johnson]. The loser would be a company that remains in the pilot-and-study phase. This would allow better-capitalized competitors to achieve similar clinical validation and strike their own large-scale deals.
If DTx giants like Pear Therapeutics (re-emerging from assets) or Big Health begin to integrate camera-based biomarkers through partnerships, they could rapidly outflank Mobio's technological wedge with superior distribution.
Data Accuracy: YELLOW -- Competitor landscape analysis is based on public market knowledge; Mobio's specific claims of clinical validation and dataset size are sourced solely from the company.
Opportunity
PUBLIC The prize for Mobio Interactive is the potential to become the first widely adopted, hardware-free standard for objective mental health assessment and therapy. It would turn the subjective, self-reported nature of psychiatric care into a quantifiable, data-driven discipline.
The headline opportunity is for Mobio to define the category of digital theragnostics. It would become the default platform for payors and providers seeking to manage mental health costs with objective biomarkers.
This outcome is reachable because the company's core technical wedge, remote photoplethysmography (rPPG) via smartphone camera, addresses a fundamental gap in the market: the lack of scalable, objective measures for mental states [Mobio Interactive]. Its validation in over 20 clinical studies provides a foundation of scientific credibility. This is rare for a digital health startup at this stage and a necessary precursor for adoption by conservative healthcare institutions [Mobio Interactive].
The backing from J&J Impact Ventures, an investor with deep pharmaceutical and medical device distribution channels, signals that a major industry player sees a path to scaling this technology [Johnson & Johnson, ~2023].
Growth could follow several concrete paths, each hinging on a specific catalyst.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Payor-Led Prevention | Health insurers and employers embed Mobio's assessment tools into wellness programs to reduce claims for stress-related conditions. | A major insurance provider in Asia-Pacific announces a partnership covering Mobio's platform for a large member base. | The company explicitly targets payors for "cost-saving prevention" and has a dedicated section of its website outlining this value proposition [Mobio Interactive]. |
| Telehealth Integration | Mobio's rPPG technology becomes a standard feature within major telehealth platforms, providing clinicians with an objective vital sign for mental health during virtual consultations. | Integration with a leading telehealth network in a key market like Singapore or Australia. | The platform is designed for remote use and targets "telehealth networks" as a core customer segment [Perplexity Sonar Pro]. |
| Government Public Health Deployment | A national health service adopts Mobio's tools for population-level mental health screening, particularly in schools or primary care settings. | A pilot program funded by a government health ministry leads to a broader procurement contract. | The company's mission emphasizes "infrastructural impact in global mental health" and it lists working with "government organisations" as part of its career opportunities [Mobio Interactive]. |
Compounding for Mobio would manifest as a data and validation flywheel. Each new deployment, whether through a payor, telehealth partner, or public health program, would generate more real-world scans.
This expanding proprietary dataset of facial rPPG signals paired with clinical outcomes would continuously improve the AI's accuracy and predictive power. Stronger validation results from this larger dataset would lower the perceived risk for the next, larger institutional customer. This would make regulatory approvals and clinical guidelines easier to secure.
Early evidence of this flywheel starting is the claim of over 425,000 scans and 3.5 million data points already collected, though this figure is self-reported [ImpactAlpha].
The size of the win, should a payor-led or telehealth integration scenario play out, can be contextualized by looking at comparable digital mental health platforms. Companies like Talkspace and BetterHelp, which focus on therapy delivery via self-report, have reached public market valuations in the hundreds of millions to billions of dollars.
A platform like Mobio, which aims to add an objective, diagnostic layer to that value chain, could command a premium for its potential to reduce systemic healthcare costs. If it captures even a single-digit percentage of the global digital mental health market, which some analysts project to exceed $20 billion by 2027, the resulting enterprise value could reach a significant multiple of its current modest funding (scenario, not a forecast) [Perplexity Sonar Pro].
Data Accuracy: YELLOW -- Core opportunity thesis is supported by company positioning and investor backing, but specific traction metrics and partnership details are limited to company sources.
Sources
PUBLIC
[PitchBook] Mobio Interactive 2026 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/130579-57
[Mobio Interactive, Unknown] Mobio Interactive | https://www.mobiointeractive.com/
[The Org, Unknown] The Org | https://theorg.com/
[Crunchbase, Unknown] Mobio Interactive - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/mobio-interactive
[Johnson & Johnson, ~2023] J&J Impact Ventures invests in Mobio Interactive | https://www.jnj.com/impact-ventures/j-j-impact-ventures-invests-in-mobio-interactive-unlocking-the-benefit-of-precision-psychiatry-at-scale-for-patients-and-healthcare-workers-around-the-world
[MobiHealthNews, Unknown] Digital health startup Mobio Interactive secures $1.8M in seed funding | https://www.mobihealthnews.com/news/asia/digital-health-startup-mobio-interactive-secures-18m-seed-funding
[Mobio Interactive, Aug 2023] Mobio Interactive Blog | https://www.mobiointeractive.com/blog/
[LinkedIn, Unknown] Mobio Interactive | LinkedIn | https://sg.linkedin.com/company/mobio-interactive
[ImpactAlpha, Unknown] J&J Impact Ventures backs Mobio Interactive to expand low-cost mental healthcare | https://impactalpha.com/jj-impact-ventures-backs-mobio-interactive-to-expand-low-cost-mental-healthcare/
[Grand View Research, 2023] Global Digital Therapeutics Market Size Report, 2023 - 2030 | https://www.grandviewresearch.com/industry-analysis/digital-therapeutics-market
[World Health Organization] World Health Organization Mental Health | https://www.who.int/health-topics/mental-health
[Perplexity Sonar Pro] Perplexity Sonar Pro Brief | https://www.perplexity.ai/
Articles about Mobio Interactive
- Mobio Interactive Is Selling Stress Readings From a 30-Second Selfie — The Singapore-based startup's AI platform uses phone cameras to measure psychological biomarkers, aiming to bring objective data to a field dominated by subjective surveys.